Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, October 18, 2016

Actinium Pharmaceuticals (NYSE: $ATNM) Granted Orphan Designation from the European Medicines Agency for Iomab-B

Actinium Pharmaceuticals (NYSE: $ATNM) Granted Orphan Designation from the European Medicines Agency for Iomab-B

·        Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
·        Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
·        Iomab-B now has orphan designation in the US and EU



NEW YORK - October 18, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company’s lead asset, Iomab-B, has been granted orphan designation in the European Union (EU) by the European Medicines Agency (EMA).

Iomab-B is intended to be used, upon approval, in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55 for a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT). Iomab-B is currently in a 150 patient multicenter, pivotal Phase 3 trial that is being conducted in the United States.

"We are excited to have been granted orphan designation in the EU for Iomab-B, which comes in addition to the SME status Actinium was granted and orphan designation for Iomab-B in the U.S.," stated Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "We believe Iomab-B represents a potentially revolutionary therapy for relapsed or refractory AML patients who are over the age of 55 who could benefit from a bone marrow transplant, which is a drastically underserved patient population. With additional regulatory support for Iomab-B in the EU through orphan designation and SME status we hope to one day bring Iomab-B to the patients of the EU."

The EMA grants orphan designation to rare diseases that are defined as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. With an estimated 30 million people living in the EU this equates to approximately 250,000 people or less for each rare disease.


About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.




Friday, October 7, 2016

#Biotech #Stocks $ACRX, $ADMA, $AIQ, $APRI, $AST, $AUPH, $AVEO, $AVIR, $AXSM, $VIVE Added to #Investorideas

Investorideas Sector Updates in #Biotech, #Technology, #Mining, #Homebuilder/ #Construction and #Luxury Brand Stocks

#Biotech #Stocks $ACRX, $ADMA, $AIQ, $APRI, $AST, $AUPH, $AVEO, $AVIR, $AXSM, $VIVE Added to #Investorideas



Point Roberts, WA, Delta BC – October 7, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories within biotech, technology, mining, homebuilder/construction and luxury brand stocks.

Biotech companies added to the global stock directories include biopharmaceutical and pharmaceutical companies, a stem cell technology company, a woman’s health company and a healthcare services provider.

New Luxury brands added range from top fashion names to interior design and high-end cooking supplies & equipment.

Technology companies added are focused on cloud computing, while mining encompasses an iron project in Canada and a venture capital firm investing in publicly-traded natural resource companies. The newest homebuilder stock Manitex International, Inc. (NasdaqCM:MNTX) supplies specialized equipment to the construction industry.


Biotech Companies Additions :
AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), ADMA Biologics, Inc. (NasdaqCM:ADMA), Alliance Healthcare Services, Inc. (NasdaqGM:AIQ), Apricus Biosciences, Inc. (NasdaqCM: APRI), Asterias Biotherapeutics, Inc. (NYSE MKT: AST), Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH), AVEO Pharmaceuticals, Inc. (NasdaqGS: AVEO), Aviragen Therapeutics, Inc. (NasdaqGS: AVIR), Axsome Therapeutics, Inc. (NasdaqCM:AXSM) and Viveve Medical Inc. (NasdaqCM:VIVE)

Luxury Stocks :
Salvatore Ferragamo SpA (Milan: SFER.MI), Moncler SpA (Milan: MONC.MI), Ethan Allen Interiors Inc. (NYSE: ETH), VF Corp. (NYSE:VFC) and Williams-Sonoma Inc. (NYSE:WSM).    

Technology Companies :
Issuer Direct Corp. (NYSE MKT: ISDR) is a market leader and innovator of Disclosure Management Systems and Cloud–based Compliance Technologies. The Company’s flagship technology platform – the Disclosure Management System (DMS) – is a secure cloud based workflow compliance collaboration system for compliance and communications professionals. Today, Issuer Direct works with several thousand compliance professionals and corporate issuers worldwide.

Callidus Software Inc. (NasdaqGM:CALD) doing business as CallidusCloud®, is the global leader in cloud based sales, marketing, learning and customer experience solutions. CallidusCloud enables organizations to accelerate and maximize their lead to money process with a complete suite of solutions that identify the right leads, ensure proper territory and quota distribution, enable sales forces, automate configure price quote, and streamline sales compensation -- driving bigger deals, faster. Approximately 4,800 leading organizations, across all industries, rely on CallidusCloud to optimize the lead to money process to close more deals for more money in record time.

Mining Companies :
Cap-Ex Iron Ore Ltd. (TSX::CEV.V) is a Canadian listed company, focused on the development of its Block 103 Iron Ore Property in the Labrador Trough, near the mining town of Schefferville, Quebec. The Block 103 property is strategically located close to an existing railway, which can provide a direct link to a shipping port, and is adjacent to New Millennium Iron Corp-Tata Steel LabMag and KeMag deposits and the New Millennium-Tata oxide deposits to the east.

Elysee Development Corp. (TSX:ELC.V) is a diversified investment and venture capital firm with a focus on publicly traded companies in the natural resource sector.

Homebuilder Companies :
Manitex International, Inc. (NasdaqCM:MNTX) is a leading worldwide provider of highly engineered specialized equipment including boom trucks, cranes, container handling equipment and reach stackers, and other related equipment. Our products, which are manufactured in facilities located in the USA and Italy, are targeted to selected niche markets where their unique designs and engineering excellence fill the needs of our customers and provide a competitive advantage. We have consistently added to our portfolio of branded products and equipment both through internal development and focused acquisitions to diversify and expand our sales and profit base while remaining committed to our niche market strategy. Our brands include Manitex, CVS Ferrari, PM, Badger, Sabre, and Valla. ASV, our Joint Venture with Terex Corporation, manufactures and sells a line of high quality compact track and skid steer loaders.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411



Friday, September 30, 2016

#Biotech #Stocks Added to #Investorideas: $ETRM, $OBMP, $PTGX

#Biotech #Stocks Added to #Investorideas: $ETRM, $OBMP, $PTGX

Sector Updates in #Biotech, #Technology, #Defense, #Mining, #Energy and #China-#Asia Stocks


Point Roberts, WA, Delta BC – September 29, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories within biotech, technology, mining, defense, energy and China-Asia.

Biotech companies include those involved in the battle against cancer, a company focused on oral peptide drugs for IBS and related GI diseases and a medical device company focused on the treatment of obesity and metabolic diseases.

Technology companies include software and social media companies along with Adesto Technologies (NasdaqCM:IOTS), which is focused on solutions to help customers usher in the era of the Internet of Things (IoT).

Mining sector additions are all TSX Venture listed companies with operations focused in Japan, Canada and Brazil respectively.

Other companies of interest include Mission Ready Services Inc (TSX: MRS.V), a Canadian defense sector company providing personal protection equipment, GRIDSUM HOLDING INC. (NasdaqGS:GSUM), a China-Asia software technology company and Perisson Petroleum Corporation (TSX:POG.V), which is involved in oil and gas exploration and development in Colombia.


Biotech Companies Added:
EnteroMedics, Inc. (NasdaqCM: ETRM), 4SC (XETRA: VSC.DE), OncBioMune Pharmaceuticals, Inc. (OTC:OBMP) and Protagonist Therapeutics, Inc. (NasdaqGM: PTGX)  

Technology Companies Added:
GRIDSUM HOLDING INC. (NasdaqGS:GSUM), Adesto Technologies (NasdaqCM:IOTS) and Agora Holdings, Inc. (OTC: AGHI)

Mining Companies Added:
Japan Gold Corp. (TSX:JG.V), RT Minerals Corp. (TSX:RTM.V) and TriStar Gold Inc. (TSX:TSG.V)

Defense Stock Added:
Mission Ready Services Inc (TSX: MRS.V) mission is to save lives and enhance the performance of military personnel, first responders, and those who protect us by working to ensure they are equipped with the best possible personal protective equipment. Headquartered in Vancouver, BC, Mission Ready has three distinct, synergistic operating divisions: Strategic consulting services and manufacturers representation/Equipment inspection, cleaning/decontamination and repair services of personal protection equipment/ Product research and development. Mission Ready's management team offers over 100 years of combined industry experience and is composed of industry experts in developing products, contracting, and selling to the federal government, first responders and tactical markets through open market procurements, teaming arrangements, and a variety of federal contract tools.

China-Asia Stock Added:
GRIDSUM HOLDING INC. (NasdaqGS:GSUM) is a leading provider of sophisticated data analysis software for multinational and domestic enterprises and government agencies in China.

Energy Stock Added:
Perisson Petroleum Corporation (TSX:POG.V) is an oil and gas exploration and development company with assets located in the Middle Magdalena Basin, Colombia’s most prolific oil and gas-producing basin. The Middle Magdalena Basin has a long history of oil production dating back to the 1950s. The Corporation’s primary asset is a 100% working interest in the VMM-17 oil block license, which consists of 39,927 hectares strategically-located next to known producers, such as Shell, Lewis Energy, EcoPetrol, Canacol Energy and ExxonMobil. In 2010, over 103 km of seismic data was acquired and interpreted, and five prospects were defined. A large portion of the license remains underexplored, having no seismic coverage whatsoever. Perisson’s strategy is to explore and develop the VMM-17 license into a world-class asset for the benefit of the Corporation and ultimately, its shareholders. To achieve this goal, the Corporation can count on an experienced management team and top-rated consultants with the knowledge required for this type of geology and environment, as well as funding from large institutional investors.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411


Thursday, September 29, 2016

Actinium (NYSE: $ATNM) Announces Pricing of Public Offering of Common Stock

Actinium (NYSE: $ATNM) Announces Pricing of Public Offering of Common Stock



NEW YORK - September 29, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016, subject to customary closing conditions.

The gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical trials, such as Iomab™-B and Actimab™- A, preclinical trials, and to meet working capital needs.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as co-manager for the offering. ROTH Capital is acting as a financial advisor for the offering.

The offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective by, the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete information about Actinium and the offering. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and, when available, the prospectus supplement and the accompanying prospectus may also be obtained from the offices of H.C. Wainwright & Co., LLC by emailing placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.


About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.



Tuesday, September 27, 2016

Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDA

Protocol revisions agreed to by the FDA include the use of peripheral blast burden as an inclusion criteria, the mandated use of Hydroxyurea in patients with high peripheral blast burden and the elimination of low dose cytarabine

Trial will enroll 53 patients in a multicenter, open-label study designed to evaluate patient complete response rates and overall survival



NEW YORK - September 27, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program consists of the CD33 targeting monoclonal antibody, HuM195, and the alpha-emitting radioisotope, actinium-225.

"We are excited to have initiated the Phase 2 trial of Actimab-A for elderly patients who are newly diagnosed with AML and ineligible for 7+3 treatment. These older patients face a poor prognosis and have limited viable treatment options" said Sandesh Seth, Actinium's Executive Chairman. "We are encouraged by the safety and efficacy signals we have seen thus far and look forward to the execution of this trial with an eye toward interim and top-line results which are both expected in 2017."

This Phase 2 clinical trial is a multicenter, open-label study that will enroll 53 patients. Patients will receive 2.0 µCi/kg/fractionated dose of Actimab-A via two injections given at day 1 and day 7. The Phase 2 trial is designed to evaluate complete response rates at up to day 42 after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017 with topline results expected in the second half of 2017. The Phase 2 trial will include peripheral blast burden as an inclusion criteria and in patients with high peripheral blast (PB) burden, the use of Hydroxyurea will be mandated with the goal of bringing PB burden below a key threshold number that the Company has identified from two previously complete Phase 1 clinical trials totaling 38 patients. In addition, the use of granulocyte colony-stimulating factors (GCSF) will be mandated. Low dose cytarabine has been eliminated from the protocol and the Phase 2 clinical trial will evaluate Actimab-A as a monotherapy. The secondary endpoint of the Phase 2 trial will be overall survival.

Dr. Joseph Jurcic, Principal Investigator of the Actimab-A Phase 2 trial and Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center said, "Actimab-A has been studied in two clinical trials thus far in patients with AML ranging in age from 18-87 who had a wide array of genetic risk factors that were at various stages of disease progression. Actimab-A has shown a promising safety and efficacy profile thus far that we believe differentiates Actimab-A from other CD33 targeting drug candidate, which is an exciting space in AML. Our PB burden hypothesis indicates that of all factors related to AML including age, stage of disease and genetic factors, peripheral blast burden showed to be the most relevant. With PB burden serving as an inclusion criteria in this Phase 2 trial and the use of Hydroxyurea being mandated in patients with PB burden above a key threshold we look forward to conducting this clinical trial in this older patient population that has a great unmet medical need."

The Company will host a webinar Tuesday, September 27, 2016 at 9:00 AM ET to discuss the Phase 2 clinical trial. Details for the webinar are as follows:

Date: Tuesday, September 27, 2016 
Time: 9:00 AM ET
 
Webinar Link:
 https://onecast.thinkpragmatic.com/ses/awQiM-9OD7Iysoul6ZD6BQ~~ 
Speakers: Joseph Jurcic, M.D., Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center
Actimab-A Principal Investigator
 
Sandesh Seth, Executive Chairman, Actinium Pharmaceuticals
 
Dragan Cicic, M.D., Chief Medical Officer, Actinium Pharmaceuticals


About Actimab-A
Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.








Monday, September 26, 2016

Actinium Pharmaceuticals (NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant



NEW YORK - September 26, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has sponsored and will participate in the upcoming Be The Match® Walk+Run being held on Saturday, October 1, 2016, at Firefighter's Field on Roosevelt Island, New York, New York. The goal of the Walk+Run is to raise awareness for bone marrow transplant (BMT), raise funds to help transplant patients, support marrow transplant research and add more potential marrow donors to the Be The Match Registry®.

Employees of Actinium Pharmaceuticals, together with their family and friends, will be participating in the Be The Match® Walk+Run to raise awareness and funds. To support Team Actinium and Be The Match® , please visit Actinium's team page here: Click here to view the team page for Team Actinium

"Actinium is focused on developing products which may improve the lives of patients with leukemia, lymphoma or one of the many other life-threatening diseases that could benefit from a bone marrow transplant," stated David Gould, M.D., Actinium's Senior Vice President of Corporate Development and Corporate Affairs. "Be The Match provides incredible support to these patients and we are honored to have the ability to sponsor such a worthwhile event and we are excited to participate in the Walk+Run on October first."

About Be The Match®
For people with life-threatening blood cancers—like leukemia and lymphoma—or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidance before, during and after transplant.

Be The Match is operated by the National Marrow Donor Program® (NMDP), a nonprofit organization that matches patients with donors, educates health care professionals and conducts research so more lives can be saved. To learn more about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2


About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Be the Match Foundation®
Melissa Neill
Strategic Public Relations Specialist
763-406-8762

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.